RWE Connect
Editorial

RWE Connect Sponsorship Guide: Benefits, Audience & ROI

Sponsoring a conference is a commercial decision. The question is not whether a conference has an audience. It is whether that audience includes people who can actually move a business decision forward.

APublished 5 min read

RWE Connect 2026 answers that question directly. Taking place on 14 to 15 October 2026 in Boston, it is a purpose-built forum for the real-world evidence community: pharma and biotech leaders, data scientists, market access professionals, regulatory teams, and the technology and data companies that serve them. Two hundred-plus attendees. Forty-plus speakers. A two-day programme designed to produce conversations, not just content.

This guide covers the audience profile, sponsorship benefits, and the ROI case for companies considering a commercial position at RWE Connect 2026.

Who Is Actually in the Room: The Speakers

Sponsorship value begins with audience quality. At RWE Connect 2026, the delegate and speaker profile reflects the seniority and functional specificity that turns conference presence into business outcomes.

Pharma and biotech leaders attend at VP, Director, Head of Department, and Executive Director level. Confirmed speakers include the Head of RWE at Boehringer Ingelheim, the Executive Director and Head of Global HEOR at BioMarin, the Global Head of HEOR at Alcon, the National Director of HEOR at Bayer, and HEOR Directors from Gilead Sciences across Oncology and Inflammatory Diseases. These are professionals with budget authority and the ability to make or recommend partnership decisions.

Medical affairs and market access teams are represented by participants from Novo Nordisk, UCB, Alnylam, and Otsuka Precision Health, reflecting the functional crossover between evidence generation and commercial access strategy.

Data science and analytics professionals attend alongside their pharma counterparts. These attendees are actively evaluating tools, platforms, and methods, often with procurement conversations already in progress.

Consulting, CRO, and research professionals represent the intermediary layer that influences and executes pharma evidence strategies.

The result is a room where buyers, decision-makers, practitioners, and solution providers share the same agenda. That overlap is where commercial conversations start.

What the Companies Already Sponsoring Have Figured Out

The companies committed to RWE Connect 2026 are not hedging. They are making a calculated bet on where their target buyers will be in October.

Truveta (Platinum Sponsor) aggregates de-identified EHR data from health systems across the US. Its headline position at RWE Connect signals where it wants to have enterprise partnership conversations: in front of senior pharma HEOR and RWE leads who are evaluating data infrastructure decisions.

Magnolia Market Access (Gold Sponsor) works at the intersection of market access strategy and evidence generation. Its sponsorship puts the firm directly in front of pharma market access leads who are actively looking for evidence strategy support.

Forian (Silver Sponsor) provides health data analytics and intelligence platforms. Its position at RWE Connect targets the data and analytics buyers in the room.

Arcadia (Thought Leadership Partner) has chosen a programme-integrated position, maximising visibility through content rather than pure brand presence.

Each of these companies evaluated the audience and concluded that 200-plus senior RWE professionals in one room justifies the investment. That same logic applies regardless of which tier you are considering.

What Do Sponsors Actually Get?

RWE Connect 2026 offers a structured sponsorship programme across multiple tiers. The core benefits are built around one principle: access that produces results.

Dedicated Speaking Slot

Present your case study, product insight, or point of view directly to a room of senior RWE professionals. Twenty minutes in that room delivers something a LinkedIn campaign or a cold outreach sequence cannot replicate.

Exhibition Space Within the Conference Flow

The exhibition zone is positioned inside the event, not beside it. Attendees pass through during breaks, lunch, and session transitions. For technology and data companies, that placement is how product conversations start naturally.

Structured 1:1 Meetings via the Partnering Lounge

Pre-scheduled, private, and purposeful. These are not hallway introductions. They are the equivalent of a targeted business development call, conducted in person, with context already established.

Pre-qualified Lead Access

Sponsors receive attendee information before the event. Commercial conversations can begin before the first session opens, not during a rushed break on day two.

Programme-wide Brand Integration

Sponsor recognition across event communications, the conference website, and session materials extends visibility well beyond the two days in Boston.

Full Networking and Social Programme Access

Dinners, roundtables, and structured breakouts are where professional relationships actually form. Sponsors are full participants, not observers.

How to Think About Your Return on Investment

Conference sponsorship ROI depends on three variables: audience quality, engagement structure, and topic alignment. RWE Connect 2026 is built to perform on all three.

Audience quality. One productive meeting with a Head of Global HEOR or a VP of Market Access can justify sponsorship investment on its own. The delegate profile at RWE Connect is not aspirational. It is confirmed.

Engagement structure. Speaking slots, the exhibition zone, the Partnering Lounge, and pre-qualified lead access create multiple commercial touchpoints across the event. Sponsors are active participants in the programme, not passive brand presences.

Topic alignment. RWE Connect is organised around eight commercial themes: market access and value demonstration, AI and advanced analytics, data integration and interoperability, decentralised trials and patient platforms, regulatory and compliance enablement, synthetic controls and trial innovation, commercial intelligence, and patient engagement and digital health. If your company operates in any of these areas, the agenda is speaking directly to your buyers.

Scale. Two hundred-plus senior attendees in a two-day format means a higher ratio of decision-makers to exhibitors than you will find at a broad pharma event. Commercial access is proportionally easier.

Location. Boston is where the US life sciences industry concentrates. Biopharma headquarters, R&D centres, academic medical institutions, and RWD companies are all in or around the city. For sponsors operating in the US life sciences market, the location removes friction and maximises the likelihood of high-value attendance.

The Types of Companies That Get the Most Out of Sponsoring

The commercial case for sponsorship is strongest for companies in the following categories.

  • Real-world data platforms and aggregators looking to open enterprise pharma partnerships with senior RWE and HEOR decision-makers.
  • AI and analytics technology companies whose products address evidence generation, data quality, predictive modelling, or regulatory documentation in pharma and biotech contexts.
  • Market access and evidence generation consultancies targeting HEOR, RWE, and medical affairs leads at pharma and biotech companies.
  • CROs and evidence study providers looking to engage clinical development, RWE, and regulatory teams at companies with active outsourcing decisions.
  • Health data and interoperability technology companies whose platforms support EHR aggregation, registry access, or real-world data standardisation.
  • Patient engagement and digital health platforms working with pharma on decentralised studies, digital endpoints, and patient-reported outcomes capture.

If your buyers are in the RWE ecosystem, they will be in Boston in October.

The people in this article will be on stage in LondonRWE Connect London 2027, 13 to 14 April, with the MHRA and the ABPI confirmed.
View the Edition

Securing Your Sponsorship Position

Platinum and Gold positions offer the highest level of programme integration and are allocated on a first-confirmed basis. Availability at these tiers is limited.

To review the prospectus or discuss commercial fit, contact the RWE Connect team at rweconnect.com/sponsor.

The event takes place 14 to 15 October 2026 in Boston. The audience is confirmed. The format is built for commercial outcomes. The only question is whether your company is in the room.

Explore sponsorship at RWE Connect 2026 →

Stay Informed

New Articles and Editions, a Few Times a Year

Session write-ups, regulator perspectives and the next edition's announcements. No more than one email a month.

You are on the list. The next article will find you.
A
About the AuthoradminWriter, RWE Connect Editorial
Keep Reading

Related Articles

RWE CONNECT · EDITORIALHello world!12 OCTOBER 2026 · 1 MIN READ · staging.rweconnect.com

Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

A
admin12 October 2026 · 1 min read
RWE CONNECT · EDITORIALThe 10 Best Real-WorldEvidence (RWE) Conferences toAttend in 202613 JULY 2026 · 8 MIN READ · staging.rweconnect.com

The 10 Best Real-World Evidence (RWE) Conferences to Attend in 2026

Real-world evidence has moved from a supporting role to a strategic imperative. Regulators are expanding its use in submissions. Payers are demanding it for reimbursement. HTA bodies are building it into evaluation frameworks. For pharma, biotech, and data science professionals, the question is no longer whether RWE matters. It is where to go to stay ahead of how it is being applied.

A
admin13 July 2026 · 8 min read
RWE CONNECT · EDITORIALTop 10 RWE, HEOR & MarketAccess Conferences for PharmaProfessionals in 202613 JULY 2026 · 7 MIN READ · staging.rweconnect.com

Top 10 RWE, HEOR & Market Access Conferences for Pharma Professionals in 2026

The relationship between real-world evidence, health economics, and market access has tightened. Payers want outcomes data. HTA bodies are embedding RWE into joint assessments. Regulators are expanding guidance on what counts as credible real-world data. For pharma professionals working across these functions, staying current is no longer enough, the work requires active engagement with how standards, methods, and policy expectations are shifting in real time.

A
admin13 July 2026 · 7 min read
Next Edition

Meet the People Behind the Evidence

Regulators, HTA bodies, payers and global evidence heads, in one room, in London on 13 to 14 April 2027.

Register for London 2027